Immunocytochemical Detection of the CD138/Syndecan-1 Antigen and Characterization of Morphologic, Phenotypic, and Viral Features of Lymphomatous Effusions
| Sample* . | CD138† . | Diagnosis . | Phenotype . | HIV‡ . | EBVρ . | KSHVρ . |
|---|---|---|---|---|---|---|
| Primary lymphomatous effusions | ||||||
| 1 | + | PEL | Non-B, non-T | + | + | + |
| 2 | + | PEL | Non-B, non-T | + | − | + |
| 3 | + | PEL | Non-B, non-T | + | + | + |
| 4 | + | PEL | Non-B, non-T | − | − | + |
| 5 | + | PEL | Non-B, non-T | + | + | + |
| 6 | − | PEL | B | − | − | + |
| 7 | − | PEL | B | + | + | + |
| HBL-6 | + | PEL | Non-B, non-T | + | + | + |
| BC-1 | + | PEL | Non-B, non-T | + | + | + |
| BC-2 | + | PEL | Non-B, non-T | + | + | + |
| BCBL-1 | + | PEL | Non-B, non-T | + | − | + |
| CROAP-2 | + | PEL | Non-B, non-T | + | + | + |
| 8 | − | DLCL | Non-B, non-T | − | − | − |
| 9 | − | DLCL | Non-B, non-T | + | + | − |
| 10 | − | SNCCL | B | − | + | − Secondary lymphomatous effusions |
| 11 | − | SNCCL | B | − | − | − |
| 12 | − | SNCCL | B | + | − | − |
| 13 | − | DLCL | B | − | − | − |
| 14 | − | DLCL | B | − | − | − |
| 15 | − | DLCL | B | − | − | − |
| 16 | − | DLCL | B | + | + | − |
| 17 | − | DLCL | B | + | + | − |
| 18 | − | DLCL | B | − | − | − |
| 19 | − | DLCL | B | − | − | − |
| 20 | − | DLCL | B | − | − | − |
| Sample* . | CD138† . | Diagnosis . | Phenotype . | HIV‡ . | EBVρ . | KSHVρ . |
|---|---|---|---|---|---|---|
| Primary lymphomatous effusions | ||||||
| 1 | + | PEL | Non-B, non-T | + | + | + |
| 2 | + | PEL | Non-B, non-T | + | − | + |
| 3 | + | PEL | Non-B, non-T | + | + | + |
| 4 | + | PEL | Non-B, non-T | − | − | + |
| 5 | + | PEL | Non-B, non-T | + | + | + |
| 6 | − | PEL | B | − | − | + |
| 7 | − | PEL | B | + | + | + |
| HBL-6 | + | PEL | Non-B, non-T | + | + | + |
| BC-1 | + | PEL | Non-B, non-T | + | + | + |
| BC-2 | + | PEL | Non-B, non-T | + | + | + |
| BCBL-1 | + | PEL | Non-B, non-T | + | − | + |
| CROAP-2 | + | PEL | Non-B, non-T | + | + | + |
| 8 | − | DLCL | Non-B, non-T | − | − | − |
| 9 | − | DLCL | Non-B, non-T | + | + | − |
| 10 | − | SNCCL | B | − | + | − Secondary lymphomatous effusions |
| 11 | − | SNCCL | B | − | − | − |
| 12 | − | SNCCL | B | + | − | − |
| 13 | − | DLCL | B | − | − | − |
| 14 | − | DLCL | B | − | − | − |
| 15 | − | DLCL | B | − | − | − |
| 16 | − | DLCL | B | + | + | − |
| 17 | − | DLCL | B | + | + | − |
| 18 | − | DLCL | B | − | − | − |
| 19 | − | DLCL | B | − | − | − |
| 20 | − | DLCL | B | − | − | − |
Abbreviations: +, positive; −, negative; DLCL, diffuse large-cell lymphoma; SNCCL, small noncleaved cell lymphoma; PEL, primary effusion lymphoma.
Pathologic samples derived from patients are indicated by numbers; cell lines are indicated by their conventional denomination.
As assesseed by immunostaining with the B-B4 MoAb.
Host HIV status as defined by standard serologic assays.
ρ Tumor cell infection as defined by a combination of in situ hybridization, Southern blot analysis, and PCR studies.